Mayer Winkler

Lastest Stories by Mayer Winkler

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
Analysts expect the price of lithium to explode over the coming decade as the growth in electric vehicles fuels demand for the metal.
At this point, bad news is coming in consistently to the point that any significant piece of good news could catapult Sanofi stock higher, making it an interesting choice for dip-buyers.
Some see the Anheuser-Busch, SABMiller deal as representative of the growing shift toward craft brews and the pressure that this shift puts on the behemoths in the space to consolidate and cut costs.
Existing home sales data out of the United States last week revealed the strongest growth rate since the beginning of 2007. That bodes well for real estate stocks.
A new JPMorgan study suggests that the reduction in average gas prices in the United States has not resulted in an increase in savings.
China just surprised the markets by reporting an unexpected rise in capital inflows. It could signal the stabilization of the second largest economy in the world.
Employment data out of the United States came out better than expected this week. Here are three of the leading recruitment stocks to look at in this tight jobs market.
New York lawmakers just voted to pass a bill that will see a young subsector of the fantasy sports space become regulated under state law. That is, daily fantasy sports, basically day trading...
With Elon Musk and Tesla Motors Inc (NASDAQ:TSLA) attempted takeover of SolarCity Corp (NASDAQ:SCTY) dominating energy headlines, the renewable sector is drawing a considerable amount of speculative...
43 years since joining the European Community in 1973, what would later become the European Union, the voters in the United Kingdom have finally voted to leave. Plenty has been written about where...
Here’s a look at how some of the public companies presenting at E3 fared, and what the rest of the year looks like in light of this.
Here's a look at which companies win and which ones lose on the latest net neutrality ruling, or at least which will be perceived as winners and losers.
Commodities look like they are about to end their half-decade slump, which may kick off a bull run that could last into the next decade.
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.